<DOC>
	<DOCNO>NCT00257621</DOCNO>
	<brief_summary>This proof concept ( POC ) single arm study GW640385 , protease inhibitor , combination RTV 2 nucleoside reverse transcriptase inhibitor ( NRTI ) backbone . This study 48 week duration open treatment naive experienced patient HIV positive . There 3 intensive pharmacokinetic ( PK ) visit .</brief_summary>
	<brief_title>GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion criterion : HIV1 infect subject . Females must either nonchildbearing potential negative pregnancy test Screening agree use protocol approve method contraception . Plasma HIV1 RNA ( viral load ) &gt; /=1,000 copies/mL Screening . CD4+ cell count &gt; /= 200 cells/mm3 Screening . Be able receive least two follow NRTIs ( 3TC , FTC , d4T , ddI ZDV ) build nucleoside backbone regimen . Willing able provide sign dated write informed consent prior study entry . Exclusion criterion : Active CDC Class C disease . Pregnant breastfeed woman . Protocolspecified laboratory abnormality Screening . Personal family history autoimmune disease . History current indication thyroid dysfunction current thyroid gland abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HIV-1 protease inhibitor GW640385 ritonavir RTV</keyword>
</DOC>